Inherited Lipodystrophies and the Metabolic Syndrome

Houshang Monajemi; Erik Stroes; Robert A. Hegele; Eric Fliers

Disclosures

Clin Endocrinol. 2007;67(4):479-484. 

In This Article

Generalized Lipodystrophy

Congenital Generalized Lipodystrophy (CGL)

CGL was first described in 1954 by Berardinelli and was further characterized by Seip, hence the eponym Berardinelli-Seip congenital lipodystrophy (BSCL).[1,3] Because the characteristic features of these patients are present at birth, CGL is usually diagnosed by neonatologists and paediatricians. Male and female subjects are affected in equal proportions. Because of the lack of subcutaneous fat, affected individuals have a masculinized appearance and soon develop acromegaloid features. Despite an excessive appetite, they usually remain lean, but frequently develop fatty liver disease that can progress to fibrosis. Early in childhood they develop pronounced insulin resistance, often leading to diabetes with concomitant dyslipidaemia. The invariably high triglyceride levels can result in recurrent episodes of pancreatitis. Approximately 300 patients with CGL have been reported to date.[4,5]

In 1999, by using a genome-wide linkage analysis of 17 pedigrees with CGL, a locus on chromosome 9q34 called BSCL1 was identified.[6] A few years later, AGPAT2 (1-acylglycerol-3-phosphate O-acyltransferase 2) was identified as the causative gene among the positional candidate genes at this locus.[7] This protein is a member of the acyltransferase family of enzymes that are involved in glycerolphospholipids and triacylglycerols. Therefore, it has been suggested that mutations in AGPAT2 could cause lipodystrophy through a direct effect on lipid biosynthesis.[8]

In 2001, Magre et al. discovered a new locus for CGL on chromosome 11q13. They analyzed 29 families from different geographical regions and in 11 families found a linkage with markers from this new locus that they called BSCL2; they showed that the causative gene within this region was GNG3L1 encoding a novel protein coined 'seipin'.[9] The function of seipin is still under investigation. In a joint effort both groups analyzed 45 families with CGL:[10] 26 had a mutation in APGAT2 while 11 had a mutation in BSCL2 (seipin), with the result that the conditions were renamed CGL1 and CGL2, respectively. Because eight families with CGL had no underlying genetic defect, it became clear that there must be additional genes underlying this phenotype. Before the detection of the genetic basis of these disorders, CGL1 and CGL2 were not considered to be distinguishable. But with molecular classification, a slight difference in clinical presentation was found: CGL2 patients appeared to have increased prevalence of mental retardation and cardiomyopathy, an observation that was subsequently confirmed by another group.[11] This clearly demonstrates the importance of collecting more CGL families for genetic analyses that could potentially lead to discovery of new causative genes.

Generalized Lipodystrophies Associated With Dysmorphic Features

Mandibulo-acral dysplasia (MAD) was first described in 1971 and is a rare autosomal recessive disorder characterized by mandibular hypoplasia, acroosteolysis, stiff joints, and cutaneous atrophy.[12] Other clinical features include postnatal growth retardation, progeroid features, and lipodystrophy with metabolic abnormalities. Because of the rarity of this disorder, little is known about the natural course or history of this disease. Following extensive clinical and biochemical analysis, as well as MRI fat measurements in four patients with MAD, Simha et al. found that three of the patients had a partial lipodystrophy characterized mainly by the loss of subcutaneous fat in the extremities, which they referred to as MAD type A.[13] The fourth patient, in contrast, had a generalized lipodystrophy that they called MAD type B; this patient was subsequently found to have compound heterozygote mutations in a zinc metalloproteinase called ZMPSTE24.[14] This enzyme plays a critical role in proteolytic cleavage of prolamin A to lamin A. Novelli et al. investigated nine individuals from five different consanguineous families with MAD and found homozygous mutations in LMNA, the gene encoding lamin A/C.[15] All MAD patients with LMNA mutations had the type A pattern of lipodystrophy. The LMNA gene encodes several nuclear lamin isoforms that play a key structural role in the nuclear envelope. Various mutations in this gene underlie a very wide range of clinical phenotypes that have been called 'laminopathies', which have been the subject of recent comprehensive reviews.[16,17]

Lipodystrophies as a Component of Progeroid Syndromes

Hutchinson-Gilford progeria syndrome (HGPS) is a rare disorder characterized by accelerated ageing. These patients are normal at birth, but age quickly, with an estimated 10 years of biological ageing per one calendar year. The average life span of these patients is approximately 13 years and they often die of cardiovascular disease. One of the characteristic features of these patients is profound atrophy of subcutaneous fat stores. There are more than 100 case reports and the incidence has been estimated to be around 1: 4-8 million.[18] Although HGPS was first described in 1886, the underlying genetic defect was found in 2003 to be a spontaneous mutation in LMNA, affecting splicing.[19]

Neonatal progeria syndrome (also called Wiedemann-Rautenstrauch syndrome) was first described by Rautenstrauch in 1977[20] and there are more than 20 case reports in the literature.[21] It is an autosomal recessive syndrome that is characterized by aged appearance at birth, with triangular face, natal teeth, hypotrichosis of the scalp hair, eyebrows and eyelashes, relative macrocephaly, micrognathia and generalized lipodystrophy. All these patients died at a young age. One patient had hyperinsulinaemia at the age of 16 months but no diabetes was reported. These syndromes are not associated with metabolic abnormalities, presumably because the patients do not survive long enough to develop the features of metabolic syndrome.

Partial Lipodystrophy

In 1974, Dunnigan reported a dominantly inherited partial lipodystrophy with metabolic abnormalities.[22] One year later, Kobberling described another type of partial lipodystrophy that was limited to the extremities.[23] More than a decade later, they proposed the first classification of familial partial lipodystrophy (FPLD).[24] Diabetes mellitus, hyperlipoproteinaemia, and acanthosis nigricans are present to a variable degree in patients with FPLD, and the abnormal distribution of subcutaneous fat is the essential hallmark of the syndrome. Most clinical detected FPLD cases were female patients and, therefore, Kobberling and Dunnigan proposed an X-linked dominant mode of transmission. Ever since, numerous case reports have been described and it has now become clear that, whereas female patients are most readily recognized clinically, male subjects are also affected.

Kobberling Type of Lipodystrophy, FPLD1

In type 1 familial lipodystrophy, loss of subcutaneous fat is confined to the limbs, sparing the face and trunk (Fig. 1). To date, no genetic mutation has been found that underlies this disease. It is generally agreed that there are more FPLD1 phenotypes than are observed. Herbst et al. elegantly demonstrated this by specifically looking for the FPLD1 phenotype.[25] They were able to identify 13 female subjects with FPLD1 within tertiary care outpatient clinics over the course of a few months by skinfold measurement of fat. This suggests that this syndrome is indeed more common than previously thought. No male subjects were identified as having FPLD1. There was a similar finding for FPLD2 until more detailed cross-sectional imaging of fat was performed.[26] These data imply that both men and women with FPLD1 are often misdiagnosed. A combination of careful clinical examination with additional imaging is required for definite recognition of these syndromes.

Figure 1.

Anatomical features of FPLD1 in an obese subject. (a) Gluteal view demonstrating central adiposity and the ledge of fat above the gluteal area (arrow). (b) Upper and lower arm demonstrating ledge of fat over triceps area (arrow). (c) Lower extremities demonstrating prominent musculature and veins. (d) Face and neck demonstrating Cushingoid appearance of the face, with moon facies and fat under chin. (Illustrated by Herbstet al. Diabetes Care2003; 26: 1819–1824: with permission of the copyright owner.)

Dunnigan Type of Lipodystrophy, FPLD2

In type 2 familial lipodystrophy the trunk is also affected, with the exception of the vulva, giving an appearance of labial hypertrophy (Fig. 2). There is usually fat hypertrophy in the neck and head region, giving the patient a Cushingoid appearance.[27] Often patients have been evaluated for Cushing's disease before lipodystrophy is considered. In 1998 Peters et al. carried out a genome-wide scan with a set of highly polymorphic short tandem-repeats (STR) in individuals from five well-characterized pedigrees and mapped the FPLD2 locus to chromosome 1q21-22.[28] Two years later, after genetic analysis of five FPLD2 probands, the causative gene was found to be LMNA,[29] again implicating nuclear lamin A in adipose metabolism.

Figure 2.

Anatomical features of FPLD2. The lipoatrophy in these patients is not confined to the extremities but also involves the trunk (face-sparing lipodystrophy). The skinfold measurements of this proband are similar to other FPLD2 subjects, falling in the low range (usually less than fifth percentile) when compared with the normal population. This explains the extreme masculine look of the proband. Increased subcutaneous fat in the neck and face creates a Cushingoid appearance. (Illustrated by Morelet al. Journal of Clinical Endocrinology and Metabolism2006; 91: 2689–2695: with permission of the copyright owner, Copyright 2006, The Endocrine Society.)

Dunnigan Type of Lipodystrophy, FPLD3

In 1999, by analysis of 85 unrelated subjects with severe insulin resistance, all coding exons of PPARγ1 and PPARγ2 were studied and new missense mutations in the ligand-binding domain of PPARγ were found in only two subjects.[30] The lipodystrophic features of those individuals were not reported at that time. In 2002, the direct link between FPLD and PPARγ was reported by two groups.[31,32] In 2003, a close evaluation of patients with the first PPARγ mutations revealed the presence of a partial lipodystrophy phenotype,[33] demonstrating how lipodystrophy can be missed during routine physical examination. Additional techniques for fat measurements (e.g. MRI) are needed to improve diagnostic accuracy, particularly in men. Since the association of PPARG with lipodystrophy, this syndrome has been annotated as FPLD3. To date 14 patients have been reported to have mutations in PPARG gene causing FPLD3.[34] Interestingly, it was recently shown that use of MRI measurements and quantification of lower extremity subcutaneous fat depots in patients with FPLD2 and FPLD3 distinguished between these two forms.[35] This corroborated the impression that there is a difference between the two and showed that subcutaneous fat loss in FPLD2 subjects was greater than in FPLD3 individuals (Fig. 3).

Figure 3.

Anatomical features of FPLD3. Although these patients also have a masculine appearance, the subcutaneous fat loss in the extremities is less obvious than in FPLD2 subjects. Furthermore, the trunk is not affected, hence the name trunk-sparing lipodystrophy. Note the Cushingoid appearance. Table 1 . Inherited lipodystrophies based upon the clinical presentation

Other FPLDs

Recently, by screening genomic DNA from 104 unrelated subjects with severe insulin resistance for mutations in genes that are implicated in insulin signalling, George et al. identified a missense mutation in the serine/threonine kinase gene AKT2 in one Caucasian proband who had a lipodystrophic phenotype.[36] This finding is consistent with the recent finding that AKT2 knockout mice develop severe diabetes and age-dependent loss of subcutaneous fat.[37] Although AKT2 can cause lipodystrophy, the prevalence of AKT2 mutations in a cohort of lipodystrophic patients was shown to be insignificant.[38]

Therapeutic Strategies

With respect to therapeutic strategies, current options are largely limited to managing metabolic abnormalities with drugs for treatment of hypertension, diabetes and dyslipidaemia. However, targeted interventions are emerging. First, administration of a specific adipokine, such as leptin, in lipodystrophic patients was shown to induce sustained improvements in glycaemia, dyslipidaemia, and hepatic steatosis.[39,40] Long-term effect of this treatment modality is currently being addressed in several centres and is very promising. A second option may be transplantation of subcutaneous fat. In fact, white adipose tissue transplantation has been shown to be effective in leptin-deficient mice.[41,42] These mice were prevented from becoming obese and had normal insulin levels. It is too soon to determine whether adipose transplantation will be effective in lipodystrophic patients. Finally, an attractive option for treating lipodystrophic patients might be the use of gene therapy. However, this therapeutic area remains unexplored at this time.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....